Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis

Author:

Bryant Andrew1,Johnson Eugenie1,Grayling Michael1,Hiu Shaun1,Elattar Ahmed2,Gajjar Ketankumar3,Craig Dawn1,Vale Luke1,Naik Raj4

Affiliation:

1. Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom;

2. Pan-Birmingham Gynaecological Oncology Cancer Centre, Birmingham, United Kingdom;

3. Nottingham City hospital, Obstetrics and Gynaecology, Nottingham, United Kingdom; and

4. Northern Gynaecological Oncology Centre, Gateshead, United Kingdom.

Abstract

Background: We present a systematic review and network meta-analysis (NMA) that is the precursor underpinning the Bayesian analyses that adjust for publication bias, presented in the same edition in AJT. The review assesses optimal cytoreduction for women undergoing primary advanced epithelial ovarian cancer (EOC) surgery. Areas of Uncertainty: To assess the impact of residual disease (RD) after primary debulking surgery in women with advanced EOC. This review explores the impact of leaving varying levels of primary debulking surgery. Data Sources: We conducted a systematic review and random-effects NMA for overall survival (OS) to incorporate direct and indirect estimates of RD thresholds, including concurrent comparative, retrospective studies of ≥100 adult women (18+ years) with surgically staged advanced EOC (FIGO stage III/IV) who had confirmed histological diagnoses of ovarian cancer. Pairwise meta-analyses of all directly compared RD thresholds was previously performed before conducting this NMA, and the statistical heterogeneity of studies within each comparison was evaluated using recommended methods. Therapeutic Advances: Twenty-five studies (n = 20,927) were included. Analyses demonstrated the prognostic importance of complete cytoreduction to no macroscopic residual disease (NMRD), with a hazard ratio for OS of 2.0 (95% confidence interval, 1.8–2.2) for <1 cm RD threshold versus NMRD. NMRD was associated with prolonged survival across all RD thresholds. Leaving NMRD was predicted to provide longest survival (probability of being best = 99%). The results were robust to sensitivity analysis including only those studies that adjusted for extent of disease at primary surgery (hazard ratio 2.3, 95% confidence interval, 1.9–2.6). The overall certainty of evidence was moderate and statistical adjustment of effect estimates in included studies minimized bias. Conclusions: The results confirm a strong association between complete cytoreduction to NMRD and improved OS. The NMA approach forms part of the methods guidance underpinning policy making in many jurisdictions. Our analyses present an extension to the previous work in this area.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Pharmacology,General Medicine

Reference106 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Ferlay;CA Cancer J Clin.,2015

2. Epidemiology of epithelial ovarian cancer;Webb;Best Pract Res Clin Obstet Gynaecol.,2017

3. Cancer of the ovary, fallopian tube, and peritoneum;Berek;Int J Gynecol Obstet.,2018

4. Cancer statistics, 2019;Siegel;CA Cancer J Clin.,2019

5. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis;Bristow;J Clin Oncol.,2002

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3